Literature DB >> 9087501

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

S A Radford1, E M Johnson, D W Warnock.   

Abstract

The in vitro activity of voriconazole was compared with that of itraconazole. Eighty-six isolates of pathogenic molds belonging to 23 species were tested by an agar dilution method in High Resolution medium. Voriconazole was more active than itraconazole against a number of hyaline molds, including several Fusarium spp. and Scedosporium prolificans. Voriconazole and itraconazole showed comparable good activity against several hyaline molds, including Penicillium marneffei and Scedosporium apiospermum, and a number of dematiaceous molds, including Bipolaris australiensis, Cladophialophora bantiana, several Exophiala spp., and several Fonsecaea spp. Our results suggest that voriconazole could be effective against a wide range of mold infections in humans.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9087501      PMCID： PMC163806     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Disseminated infection with Fusarium in recipients of bone marrow transplants.

Authors:  A S Gamis; T Gudnason; G S Giebink; N K Ramsay
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

2.  Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.

Authors:  A Valentin; R Le Guennec; E Rodriguez; J Reynes; M Mallie; J M Bastide
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient.

Authors:  V Hopwood; E G Evans; J Matthews; D W Denning
Journal:  J Infect       Date:  1995-03       Impact factor: 6.072

4.  Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

Authors:  D George; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method.

Authors:  A Gehrt; J Peter; P A Pizzo; T J Walsh
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients.

Authors:  J L Rodríguez-Tudela; J V Martínez-Suárez; F Dronda; F Laguna; F Chaves; E Valencia
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

7.  Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.

Authors:  J D Velez; R Allendoerfer; M Luther; M G Rinaldi; J R Graybill
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

8.  Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies.

Authors:  L I Lutwick; J N Galgiani; R H Johnson; D A Stevens
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

9.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
  9 in total
  41 in total

1.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

5.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

6.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors:  C J Clancy; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases.

Authors:  Graziella Hanna Pereira; Derlene Attili de Angelis; Roosecelis Araujo Brasil; Marilena dos Anjos Martins; Dulcilena de Matos Castro e Silva; Maria Walderez Szeszs; Marcia de Souza Carvalho Melhem
Journal:  Mycopathologia       Date:  2012-10-18       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.